Clinical Trial Update: Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

View source ↗

Summary

A completed clinical trial assessing the effects of monoclonal antibody treatment on post-acute COVID-19 syndrome (long COVID).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Monoclonal antibody treatment

Snippet

Sponsor: Intermountain Health Care, Inc. | Conditions: Post-acute COVID-19 (PACS), or "long COVID" Syndrome | Status: COMPLETED